Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
April 21, 2006
EGRP NEWS FLASH
From the Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
This News Flash brings you news about:
- Note! Program Announcement Numbers Change With Approaching Transition to Electronic Submission of Applications for Small Grants Program (R03) and Exploratory/Developmental Research Grants (R21)
- NCI Announces Availability of Administrative Supplements for Studies of Cancer in HIV/AIDS
- NIH Updates Instructions on Inclusion of Publications as Appendix Materials
- New Monograph on Methods for Measuring Cancer Disparities Published
- Subscribe to EGRP Bulletins and News Flashes
Note! Program Announcement Numbers Change With Approaching Transition to Electronic Submission of Applications for R03 and R21s
Several Program Announcements (PA) sponsored by the Epidemiology and Genetics Research Program (EGRP) have been reissued as the dates fast approach when the Small Grants Program (R03) and Exploratory/Developmental Research Grant (R21) funding mechanisms transition to electronic submission of applications and use of the new SF 424 (R&R) form.
Electronic submission is mandatory for R03s and R21s for the upcoming receipt dates of June 1, 2006, for non-AIDS applications, and September 1, 2006, for AIDS applications. For PARs that use these mechanisms, refer to the receipt dates specified in the announcements. (Also transitioning on the same dates are NIH Exploratory/Development Grants – Phase II (R33) and Clinical Trial Planning Grants Program (R34)).
The affected EGRP-sponsored PA/PARs are:
- PA for Pilot Studies in Pancreatic Cancer (PA-05-116,
R03 and R21), which has been reissued as:
PA-06-314 for R03s, April 4, 2006
PA-06-303 for R21s, March 31, 2006
EGRP Program Director: Mukesh Verma, Ph.D.; e-mail: vermam@mail.nih.gov
- PAR for Small Grants Program for Cancer Epidemiology (PAR-04-159,
R03), which has been reissued as:
PAR-06-294, March 29, 2006
Note that the upcoming receipt/transition date for this PAR is July 20, 2006 (unchanged).
EGRP Program Director: Mukesh Verma, Ph.D.; e-mail: vermam@mail.nih.gov
- PA for Malignancies in AIDS and Acquired Immune Suppression (PA-04-157,
R01, R21), which has been reissued as:
PA-06-338 for R21s, April 7, 2006
R01 applications continue to be submitted under PA-04-157.
EGRP Program Directors: Ms. Vaurice Starks; e-mail: starksv@mail.nih.gov, and Mukesh Verma, Ph.D.; e-mail: vermam@mail.nih.gov
- PA for Exfoliated Cells, Bioactive Food Components, and Cancer (PA-04-114,
R03, R21), which has been reissued as:
PA-06-360 for R03s, April 13, 2006
PA-06-359 for R21s, April 13, 2006
R01 applications continue to be submitted under PA-04-114.
EGRP Program Director: Virginia (Ginny) Hartmuller, Ph.D., R.D.; e-mail: hartmulv@mail.nih.gov
- PA for Studies of Energy Balance and Cancer in Humans (PA-04-124, R01, R21). A new PA for R21 applications is expected to be issued soon in the NIH Guide. We will alert you when it becomes available.
Please be aware that grant applications for funding under the R03 and R21 mechanisms may be submitted electronically to Grants.gov no earlier than May 2, 2006. A registration process is necessary before submission and should be started at least 4 weeks in advance of the planned submission. For further information about the transition and what to do, access:
- NIH's Electronic Submission of Grant Application (timeline, frequent updates, tips, and more)
- Videocast of "NIH's New Electronic Grant Application Process
and the SF 424 (R=R)," January 11, 2006. (Go to "Past
Events," then Special," and search by date
or title.)
Accompanying materials
- eRA Commons. (A grantee's organization must be registered before the individual investigator may do so.)
- Subscribe to NIH Extramural Nexus, a bimonthly online newsletter
NCI Announces Availability of Administrative Supplements for Studies of Cancer in HIV/AIDS
NCI's Office of AIDS Malignancy Program, Division of Cancer Treatment and Diagnosis, has set apart funds in Fiscal Year (FY) 2006 designated for studies of AIDS and HIV-associated cancers. NCI is requesting applications for administrative supplements for NCI-funded or co-funded R01, R21, P01, U01, P50, P30, and D43 grants. Depending on the merit of the requests received and the availability of funds, NCI may award up to $1 million in supplemental funding in connection with this funding opportunity announcement in FY 06. Detailed instructions for applying for the administrative supplements.
Inquiries about programmatic and review matters may be directed to: Kishor Bhatia, Ph.D., MRCPath; e-mail: bhatiak@mail.nih.gov, or Geraldina Dominguez, Ph.D., e-mail: domingug@mail.nih.gov.
Access the complete announcement in the NIH Guide, NOT-CA-06-023, April 10, 2006.
NIH Updates Instructions on Inclusion of Publications as Appendix Materials
NIH has announced a change in the approach and policy on inclusion of publications as Appendix materials in grant applications. The policy applies to all grant mechanisms for which publications are acceptable Appendix material, regardless of which application form is used (e.g., PHS 398, SF 424 (R&R), PHS 416-1) or the mode of submission (paper or electronic).
The change is effective for applications intended for the May 10, 2006, submission date. From the NIH Guide, the new NIH standard policy is:
"Publications, manuscripts (accepted for publication), abstracts, patents, or other printed materials directly relevant to the proposed project. Do not include manuscripts submitted for publication. Applicants should refer to instruction guides and specific Funding Opportunity Announcements (FOAs) to determine the appropriate limit on the number of publications that may be submitted for a particular program. Note that not all grant mechanisms allow the inclusion of publications.
- Publications in press: Include only a publication list with a link to the on-line journal article or the NIH PubMed Central (PMC) submission identification number. Do not include the entire article.
- Manuscripts accepted for publication but not yet published: The entire article may be submitted electronically as a PDF attachment.
- Manuscripts published but an online journal link is not available: The entire article may be submitted electronically as a PDF attachment.
Note at this time no changes are being made to the other Appendix components:
- Surveys, questionnaires, data collection instruments, clinical protocols, and informed consent documents.
- No images may be included in the Appendix that are not also represented within Items 2-5 of the Research Plan.
Applicants are cautioned not to use the Appendix to circumvent the page limitations of the Research Plan. An application that does not observe the relevant policies and procedures may be delayed in the review process.
Applicants are reminded to review specific FOAs for any additional program-specific guidance on Appendix material and other application requirements.
Application instructions for the PHS 398, SF 424 (R&R), and PHS 416-1 will be revised to reflect this new policy for inclusion of publications in Appendix."
Inquiries about the Notice may be directed to: GrantsInfo, NIH Office of Extramural Research; tel.: 301-435-0714, e-mail: grantsinfo@nih.gov.
NIH Guide, NOT-OD-06-051, March 16, 2006:
New Monograph on Methods for Measuring Cancer Disparities
Methods for Measuring Cancer Disparities: A Review Using Data
Relevant to Healthy People 2010 Cancer-Related Objectives is a new
monograph available online and in print from the Division of Cancer Control
and Population Sciences (DCCPS). The report raises some conceptual
issues and provides an innovative methodological approach germane to measuring
progress toward the goal of eliminating health disparities. It highlights
major issues that may affect the choice of measurement techniques and
systematically reviews methods used in health disparities research. The
authors recommend a sequence of steps to measure and monitor cancer-related
disparity trends using a suite of indicators and measurement strategies
explaining in detail the strengths and weaknesses of each.
- In most situations a single measure will not provide adequate and appropriate information for policy decisions relating to disparities in health.
- Absolute and relative measures, e.g., changes in the absolute frequency of cancer of two groups versus the changes in the relative frequency, can often lead to different conclusions about whether health disparities between these groups are increasing or decreasing.
- It is important to take into account the size of population groups or segments and their share of the total population along with the magnitude of their disparities to determine the impact of these disparities on the public health system.
This report was written under contract from the Surveillance Research Program (SRP) and the Applied Research Program (ARP) of the Division of Cancer Control and Population Sciences of the National Cancer Institute, NIH. Additional support was provided by the National Institutes of Health (NIH) Office of Disease Prevention. Access the monograph or order a print copy.
Subscribe to EGRP Bulletins and News Flashes
You are welcome to invite others to subscribe to receive occasional Bulletins and News Flashes from the Epidemiology and Genetics Research Program (EGRP).
- To subscribe to FRIENDS-OF-NCI-EGRP-L, contact lynchs@mail.nih.gov.
